These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36874988)

  • 1. A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma.
    Fukiishi Y; Fukuhara H; Kurano Y; Shugimoto H; Yamashita E; Karasima T; Inoue K
    IJU Case Rep; 2023 Mar; 6(2):128-132. PubMed ID: 36874988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
    Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
    Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
    Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.
    Miyake M; Shimizu T; Nishimura N; Kiba K; Maesaka F; Oda Y; Tachibana A; Tomizawa M; Ohmori C; Matsumura Y; Ichikawa K; Mizobuchi S; Yoshikawa T; Hori S; Morizawa Y; Gotoh D; Nakai Y; Anai S; Torimoto K; Aoki K; Tanaka N; Fujimoto K;
    Clin Genitourin Cancer; 2022 Apr; 20(2):196.e1-196.e9. PubMed ID: 34916166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
    Hale O; Patterson K; Lai Y; Meng Y; Li H; Godwin JL; Homet Moreno B; Mamtani R
    Clin Genitourin Cancer; 2021 Feb; 19(1):e17-e30. PubMed ID: 32826180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe gastritis due to pembrolizumab treatment in a lung cancer patient.
    Hayama N; Ihara H; Honma Y; Itoigawa Y; Kaira K; Fujii M
    Respirol Case Rep; 2020 Oct; 8(7):e00636. PubMed ID: 35600796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of metastatic bladder cancer by gemcitabine-cisplatin re-challenge after pembrolizumab.
    Arai T; Takeuchi N; Sazuka T; Sato H; Imamura Y; Sakamoto S; Komiya A; Ichikawa T
    IJU Case Rep; 2021 Nov; 4(6):360-362. PubMed ID: 34755056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe Gastritis after Administration of Nivolumab and Ipilimumab.
    Nishimura Y; Yasuda M; Ocho K; Iwamuro M; Yamasaki O; Tanaka T; Otsuka F
    Case Rep Oncol; 2018; 11(2):549-556. PubMed ID: 30186138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [ONE COURSE OF PEMBROLIZUMAB AFTER RADIATION THERAPY WAS VERY EFFECTIVE AGAINST METASTATIC BLADDER CANCER AND CR WAS CONFIRMED: A CASE REPORT].
    Sakamoto T; Fujimoto N; Nakashima M
    Nihon Hinyokika Gakkai Zasshi; 2021; 112(4):220-223. PubMed ID: 36261353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal observation of endoscopic and histological findings of gastritis after administration of an immune checkpoint inhibitor: a case report.
    Saito K; Ozono D; Nagumo H; Yoshimura M; Masuzawa Y
    Clin J Gastroenterol; 2022 Apr; 15(2):368-373. PubMed ID: 34985687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma.
    Hayakawa N; Kikuchi E; Suzuki S; Oya M
    Int Cancer Conf J; 2020 Jul; 9(3):123-126. PubMed ID: 32582515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
    Thomas S; Bae C; Joy-Ann T; Traverse W
    J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma.
    Fukuta K; Izaki H; Shiozaki K; Nakanishi R; Inai T; Kataoka H; Kudo E; Kanda K
    IJU Case Rep; 2021 Sep; 4(5):310-313. PubMed ID: 34497992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab.
    Hatayama T; Hayashi T; Matsuzaki S; Masumoto H; Yanai H; Abdi H; Teishima J; Hasegawa Y
    IJU Case Rep; 2020 Nov; 3(6):252-256. PubMed ID: 33163917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
    Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma.
    Patel A; Bisno DI; Patel HV; Ghodoussipour S; Saraiya B; Mayer T; Singer EA
    J Cancer Immunol (Wilmington); 2021; 3(2):115-136. PubMed ID: 34263255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evans syndrome during pembrolizumab therapy for upper urinary tract cancer.
    Kakita S; Matsuo T; Ohki M; Tsuchiyama A; Yasuda T; Nakanishi H; Mitsunari K; Ohba K; Imamura R
    IJU Case Rep; 2023 Sep; 6(5):298-301. PubMed ID: 37667757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.